Mark Stenhouse - Prometheus Biosciences Chief Officer
| RXDXDelisted Stock | USD 199.92 0.24 0.12% |
Insider
Mark Stenhouse is Chief Officer of Prometheus Biosciences
| Age | 56 |
| Phone | 858 684 1300 |
| Web | https://www.prometheusbiosciences.com |
Prometheus Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2006) % which means that it has lost $0.2006 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Prometheus Biosciences' management efficiency ratios could be used to measure how well Prometheus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Prometheus Biosciences currently holds 14.76 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Prometheus Biosciences has a current ratio of 13.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Prometheus Biosciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Johannes Hull | Pliant Therapeutics | 49 | |
| Remy Sukhija | Madrigal Pharmaceuticals | 52 | |
| Rebecca MD | Madrigal Pharmaceuticals | 72 | |
| Joshua Cohen | Amylyx Pharmaceuticals | 32 | |
| Alexis AM | Blueprint Medicines Corp | 52 | |
| Marianne Romeo | Roivant Sciences | 56 | |
| Andreas Orth | Krystal Biotech | 54 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| Dr MBA | Blueprint Medicines Corp | 54 | |
| Vivek Ramaswamy | Roivant Sciences | 39 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Rik Derynck | Pliant Therapeutics | N/A | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Julia Butchko | Immunovant | 53 | |
| Huafeng Xu | Roivant Sciences | N/A | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| Rakhi Kumar | Roivant Sciences | 44 | |
| David Tice | Arcellx | 53 | |
| Craig Muir | Pliant Therapeutics | N/A | |
| Quoc LeNguyen | 89bio Inc | 56 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 |
Prometheus Biosciences Leadership Team
Elected by the shareholders, the Prometheus Biosciences' board of directors comprises two types of representatives: Prometheus Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prometheus. The board's role is to monitor Prometheus Biosciences' management team and ensure that shareholders' interests are well served. Prometheus Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prometheus Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allison MD, Chief Officer | ||
| Noel Kurdi, VP Communications | ||
| Timothy Esq, G Sec | ||
| Chris Doughty, Chief Officer | ||
| Mark McKenna, CEO Pres | ||
| Nori Ebersole, Chief Officer | ||
| Olivier Laurent, Chief RD | ||
| MBA MBA, Chief Officer | ||
| Mark Stenhouse, Chief Officer |
Prometheus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prometheus Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (40.65) % | |||
| Current Valuation | 4.39 B | |||
| Shares Outstanding | 47.81 M | |||
| Shares Owned By Insiders | 16.61 % | |||
| Shares Owned By Institutions | 81.01 % | |||
| Number Of Shares Shorted | 4.68 M | |||
| Price To Earning | (5.66) X | |||
| Price To Book | 19.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |